Abstract
Preliminary acceptability and reliability tests of the Dalkon Shield were done in 377 women over 17 months, amounting to 3,028 months of use. There was a 98% follow-up. The pregnancy rate of 4·7 and expulsion rate of 6·3 do not meet the claims described in initial trials by the developers of the device. Nevertheless, the Dalkon Shield seems to be an advance in intrauterine contraception since it has the advantages of a lower expulsion rate than the “first generation” inert intrauterine devices.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Davis H. J. The shield intrauterine device. A superior modern contraceptive. Am J Obstet Gynecol. 1970 Feb 1;106(3):455–456. doi: 10.1016/0002-9378(70)90375-3. [DOI] [PubMed] [Google Scholar]
- Sağiroğlu N., Sağiroğlu E. Biologic mode of action of the Lippes loop in intrauterine contraception. Am J Obstet Gynecol. 1970 Feb 15;106(4):506–515. [PubMed] [Google Scholar]
- Sedlis A., Reyniak J. V. Endometrial leukocytes in patients using intrauterine contraceptive devices. Am J Obstet Gynecol. 1970 Dec 15;108(8):1209–1212. doi: 10.1016/0002-9378(70)90094-3. [DOI] [PubMed] [Google Scholar]